Opinion|Videos|August 21, 2024

Treatment Options in Castration-Resistant Prostate Cancer

Author(s)Lawrence Karsh, MD, FACS, Stephen J. Freedland, MD, Terence Friedlander, MD

Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.

Episodes in this series

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 1 Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Stephen Freedland, MD, an expert on prostate cancer

EP. 2 The Heterogeneity of Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 3 The Role of ADT in Localized or Locally Advanced Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 4 EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 5 Treatment Considerations in Nonmetastatic CSPC

Terence Friedlander, MD, an expert on prostate cancer

EP. 6 Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 7 Treatment Options in Castration-Resistant Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 8 The Relationship Between Prostate Cancer and Cardiovascular Disease

Stephen Freedland, MD, an expert on prostate cancer

EP. 9 Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 10 ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

SBRT improves multiple quality of life domains but not DFS vs MH-IMRT

ByHannah Clarke

August 18th 2026

Active surveillance use for low-risk prostate cancer reaches 93% in VA system

ByHannah Clarke

August 14th 2026

Focal therapy for prostate cancer frequently used outside guideline-supported groups

ByHannah Clarke

August 14th 2026

Registry launches to assess real-world clinical utility of ArteraAI Prostate Test

ByHannah Clarke

August 13th 2026

Higher intake of ultra-processed food is associated with increased prostate cancer risk

ByHannah Clarke

August 12th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

Study shows variability in response to long-term tamsulosin therapy

High-Risk BCG-Naive NMIBC: Where Treatment Falls Short Today

Hans Arora, MD, PhD, on improving communication in the OR